Why are cheaper Covid-19 drugs not being promoted, asks Parliamentary panel

Cutting across party lines, the committee members questioned why expensive medicines were often being recommended for Covid-19 treatment

Coronavirus, Covid
Healthcare workers collect swab samples from people residing at a slum area for COVID-19 testing in Mumbai on Saturday.
Press Trust of India New Delhi
1 min read Last Updated : Jul 15 2020 | 7:03 PM IST

A parliamentary panel told senior government officials on Wednesday to promote cheaper and easily available domestic-made medicines for COVID-19, and check recommendation and cap prices of expensive medicines pushed by pharma companies, sources said.

During a meeting of Parliamentary Standing Committee on Home Affairs, members also demanded that the maximum price of COVID-19 medicines be capped, they said.

Home Secretary Ajay Bhalla, Joint Secretary in Health Ministry Lav Agarwal and other officials were present in the meeting of the standing committee on home affairs chaired by Congress leader Anand Sharma.

Cutting across party lines, the committee members questioned why expensive medicines were often being recommended for COVID-19 treatment, sources in the panel said.

The committee members expressed concern over black marketing of medicines.

Naming three cheaper and easily available medicines, the committee members questioned why are they not being promoted despite they being equally effective.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusPharmaParliamentary panelCOVID-19

First Published: Jul 15 2020 | 6:51 PM IST

Next Story